Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Additional Information (Details)

v3.21.2
Commitments and Contingencies - Additional Information (Details)
1 Months Ended 3 Months Ended 6 Months Ended
Feb. 01, 2021
USD ($)
Milestonepayment
Aug. 17, 2020
USD ($)
Apr. 10, 2015
USD ($)
Feb. 29, 2020
USD ($)
Milestonepayment
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2021
EUR (€)
Jun. 18, 2021
USD ($)
Dec. 31, 2020
USD ($)
Dec. 20, 2020
USD ($)
Aug. 31, 2020
USD ($)
Aug. 18, 2020
USD ($)
Jun. 30, 2017
USD ($)
Supply Commitment [Line Items]                            
Guarantee liability             $ 620,000     $ 422,000        
Purchase Commitment                            
Supply Commitment [Line Items]                            
Purchase commitment non cancelable and cancelable             7,035,000              
Alkermes Plc | Amendment to Purchase and Sale Agreement                            
Supply Commitment [Line Items]                            
Milestone development earn-out consideration payable                 $ 1,440,000   $ 1,060,000 $ 5,000,000 $ 2,500,000  
Payment for one-time non-refundable and non-creditable fee   $ 285,000                        
Collaborative arrangements milestone payments upon achievement of regulatory and sales milestones             $ 21,429,000              
Alkermes Plc | Amendment to Purchase and Sale Agreement | Contingent Consideration, Third Component                            
Supply Commitment [Line Items]                            
Minimum milestone payments percentage             60.00% 60.00%            
Alkermes Plc | Amendment to Purchase and Sale Agreement | Contingent Consideration, Fourth Component                            
Supply Commitment [Line Items]                            
Maximum royalty payment percentage             30.00% 30.00%            
Alkermes Plc | Amendment to Purchase and Sale Agreement | Milestone Payments Due Beginning On First Anniversary Of Regulatory Approval | Contingent Consideration, Second Component                            
Supply Commitment [Line Items]                            
Business acquisition contingent consideration possible milestone payments $ 45,000,000                          
Business acquisition, contingent consideration, number of equal annual milestone payments | Milestonepayment 7                          
Business acquisition, contingent consideration, equal annual milestone payments $ 6,400,000                          
U.S | Cornell University | Neuromuscular Blocking Agents License Agreement                            
Supply Commitment [Line Items]                            
Regulatory approval and commercialization milestones                           $ 5,000,000
European | Cornell University | Neuromuscular Blocking Agents License Agreement                            
Supply Commitment [Line Items]                            
Regulatory approval and commercialization milestones                           $ 3,000,000
Minimum | Alkermes Plc | Amendment to Purchase and Sale Agreement | Contingent Consideration, Fourth Component                            
Supply Commitment [Line Items]                            
Royalty payment percentage             10.00% 10.00%            
Maximum | Executive Officer                            
Supply Commitment [Line Items]                            
Aggregate annual base salaries of employment agreement             $ 1,317,000              
Maximum | Alkermes Plc | Amendment to Purchase and Sale Agreement | Contingent Consideration, Fourth Component                            
Supply Commitment [Line Items]                            
Royalty payment percentage             12.00% 12.00%            
Recro | Alkermes Transaction                            
Supply Commitment [Line Items]                            
Collaborative arrangements, milestone payments upon achievement of regulatory and sales milestones     $ 140,000,000                      
Recro | Alkermes Transaction | Regulatory Approval and Net Sales Milestones                            
Supply Commitment [Line Items]                            
Collaborative arrangements, milestone payments upon achievement of regulatory and sales milestones     $ 60,000,000                      
Collaborative arrangements, milestone payments period     7 years                      
Recro | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction | Contingent Consideration, First Component                            
Supply Commitment [Line Items]                            
Business acquisition contingent consideration, first milestone payment           $ 5,000,000                
Business acquisition contingent consideration possible milestone payments         $ 5,000,000                  
Recro | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction | Contingent Consideration, Third Component                            
Supply Commitment [Line Items]                            
Minimum milestone payments percentage             60.00% 60.00%            
Recro | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction | Contingent Consideration, Fourth Component                            
Supply Commitment [Line Items]                            
Maximum royalty payment percentage             30.00% 30.00%            
Recro | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction | Milestone Payments Due, Following Regulatory Approval | Contingent Consideration, Second Component                            
Supply Commitment [Line Items]                            
Business acquisition contingent consideration possible milestone payments       $ 5,000,000                    
Recro | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction | Milestone Payments Due Beginning On First Anniversary Of Regulatory Approval | Contingent Consideration, Second Component                            
Supply Commitment [Line Items]                            
Business acquisition contingent consideration possible milestone payments       $ 45,000,000                    
Business acquisition, contingent consideration, number of equal annual milestone payments | Milestonepayment       7                    
Business acquisition, contingent consideration, equal annual milestone payments       $ 6,400,000                    
Recro | Minimum | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction | Contingent Consideration, Fourth Component                            
Supply Commitment [Line Items]                            
Royalty payment percentage             10.00% 10.00%            
Recro | Maximum | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction | Contingent Consideration, Second Component                            
Supply Commitment [Line Items]                            
Business acquisition, contingent consideration, milestone payments due period following regulatory approval       180 days                    
Recro | Maximum | Alkermes Plc | Amendment to Purchase and Sale Agreement | Alkermes Transaction | Contingent Consideration, Fourth Component                            
Supply Commitment [Line Items]                            
Royalty payment percentage             12.00% 12.00%            
Recro | Dexmedetomidine License Agreement                            
Supply Commitment [Line Items]                            
Contingent milestone payments, maximum             $ 24,349,000 € 20,500,000            
Amount of royalty payments due or payable             $ 0              
Recro | Dexmedetomidine License Agreement | Minimum                            
Supply Commitment [Line Items]                            
Percentage of royalty payments             10.00% 10.00%            
Recro | Dexmedetomidine License Agreement | Maximum                            
Supply Commitment [Line Items]                            
Percentage of royalty payments             20.00% 20.00%            
Recro | Fadolmidine License Agreement                            
Supply Commitment [Line Items]                            
Amount of royalty payments due or payable             $ 0              
Additional contingent milestones payment             $ 14,492,000 € 12,200,000            
Recro | Fadolmidine License Agreement | Minimum                            
Supply Commitment [Line Items]                            
Percentage of royalty payments             10.00% 10.00%            
Recro | Fadolmidine License Agreement | Maximum                            
Supply Commitment [Line Items]                            
Percentage of royalty payments             15.00% 15.00%